Market Place

Market Place

Market Place

Menu

Post Enquiry

Post Enquiry

PharmaCompass

Home

Market Place

Market Place

Search
All
API
FDF
Price
Services
Excipients
Enquiries

    Find

    • Active Pharmaceutical Ingredients Active Pharmaceutical Ingredients
    • Finished Drug Formulations Finished Drug Formulations
    • Price Price
    • Excipients Excipients
    • Services Services
    • Market Place Marketplace

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    Scorr-Insert
    X

    Find Drugs for Cardiology/Vascular Diseases in Preclinical Development in CANADA

    A collaboration with SCORR Marketing

    Loading...

    All Data

    Filters Filter refresh
    ×
    FILTER DATA :
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            Upfront Payment filter
              refresh

              Product Type Full Screen

              Companies Full Screen

              Primary Peptides

              • Deals

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              CANADA Canada

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              BIO International Convention

              Participation Not Confirmed

              Update your events

              Qingdao Primedicine Pharmaceutical Co. Ltd and Primary Peptides Inc. Announce Exclusive China Partnership

              Contact the Supplier

              Lead Product(s): PP-002

              Therapeutic Area: Cardiology/Vascular Diseases

              Highest Development Status: Preclinical Product Type: Large molecule

              Partner/Sponsor/Collaborator: Qingdao Primedicine Pharmaceutical

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Licensing Agreement May 19, 2020

              Details:

              Under the terms of the Partnership, Primedicine receives exclusive rights to develop and commercialize in China, including the mainland, Hong Kong, Macau and Taiwan while Primary Peptides retains rights in all other markets. Financial terms were not disclosed.

              Primary Peptides

              • Deals

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              CANADA Canada

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              BIO International Convention

              Participation Not Confirmed

              Update your events

              Simcere Pharmaceutical Group and Primary Peptides Inc. Announce Exclusive China Partnership

              Contact the Supplier

              Lead Product(s): Zarilamid

              Therapeutic Area: Cardiology/Vascular Diseases

              Highest Development Status: Preclinical Product Type: Small molecule

              Partner/Sponsor/Collaborator: Simcere Pharmaceutical

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Partnership May 11, 2020

              Details:

              Simcere receives exclusive rights to develop and commercialize in China, including the mainland, Hong Kong, Macau and Taiwan while Primary Peptides retains rights in all other markets.

              Revive Therapeutics

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              CANADA Canada

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              BIO International Convention

              Participation Not Confirmed

              Update your events

              Revive Therapeutics Provides Update on its Cannabinoid Program Initiatives for Drug Delivery and in the Prevention of Ischemia and Reperfusi...

              Contact the Supplier

              Lead Product(s): Cannabidiol

              Therapeutic Area: Cardiology/Vascular Diseases

              Highest Development Status: Preclinical Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable January 20, 2020

              Details:

              Revive is expanding its product pipeline by leveraging its FDA orphan drug designation for cannabidiol in the prevention of ischemia and reperfusion injury from organ transplantation.

              PharmaCompass__DigitalAd